Navigation Links
ARIUS recognized for entrepreneurial excellence
Date:4/7/2008

Dr. David S. Young awarded "Most Innovative" award by the Association of

Chinese Canadian Entrepreneurs

TORONTO, April 7 /PRNewswire-FirstCall/ - ARIUS Research Inc. (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that Dr. David S. Young, President and Chief Executive Officer, received the "Most Innovative" award at the Chinese Canadian Entrepreneur Awards, held on April 5th, 2008 in Toronto, Ontario.

"The FunctionFIRST(TM) antibody discovery platform pioneered by our CEO is the foundation of our company and exemplifies the exceptional innovation that this award honours," said Warren Whitehead, Chief Financial Officer of ARIUS. "As we transition to a clinical company this year, we are proud that ARIUS' mission to generate and develop anti-cancer, antibody drugs has been recognized through this honour."

The Chinese Canadian Entrepreneur Awards, sponsored by the Association of Chinese Canadian Entrepreneurs (ACCE), annually recognizes high achievements by business people and entrepreneurs who have strengthened the competitiveness of Chinese Canadian business community in the global market. The Most Innovative Award is presented to an individual, team of individuals or company who have demonstrated exceptional innovation in their given field and contributed great value to the marketplace.

About ARIUS

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 500 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit http://www.ariusmabs.com.

Forward-Looking Statements

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results expressed or implied by such statements include, but are not limited to: early stage of development; technology and product development; dependence on and management of current and future corporate collaborations; future capital needs; uncertainty of additional funding; no assurance of market acceptance; dependence on proprietary technology and uncertainty of patent protection; intense competition; manufacturing and market uncertainties; and government regulation. These and other factors are described in detail in ARIUS' Annual Report, forthcoming news releases and other filings with Canadian securities regulatory authorities available at http://www.sedar.com. Forward-looking statements are based on our current expectations and ARIUS is not obligated to update such information to reflect later events or developments.


'/>"/>
SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
2. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
3. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
4. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
5. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
6. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
7. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
8. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
9. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
10. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
11. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... expansion to their comprehensive training and support program, Sonalinkā„¢ remote monitoring. The inaugural ... procedures performed on Friday, February 5th, connecting Dr. Samuel Peretsman to a HIFU ...
(Date:2/10/2016)... ... February 10, 2016 , ... Cenna Bioscience Inc., an emerging biopharmaceutical company focused ... announced today it has been selected to present at the Cavendish Global Health Impact ... Florida. The purpose of the Forum is to help family offices and foundations ...
(Date:2/9/2016)... ... February 08, 2016 , ... Date ... S. Blumberg Institute at the Pennsylvania Biotechnology Center of Bucks County, 3805 Old ... Commonwealth Medical College (TCMC) will hold an open house for participants to learn ...
(Date:2/9/2016)... ... February 09, 2016 , ... The American Academy ... history, it is offering its 2016 AAT Member Certification Qualification Course for Technicians via ... for the webinar, which will include a detailed review of hardware, software, and camera ...
Breaking Biology Technology:
(Date:2/3/2016)... 2016 Vigilant Solutions announces today that the ... Missouri solved two recent hit-and-run cases ... from Vigilant Solutions. Brian Wenberg explains, ... victim was walking out of a convenience store and witnessed an elderly male ... vehicle, striking his vehicle and leaving the scene.  In ...
(Date:2/2/2016)... Checkpoint Inhibitors for Cancer – Explore ... you interested in the future of cancer drugs? ... Visiongain,s report gives those predictions to 2026 at ... Avoid falling behind in data or losing ... those emerging cancer therapies can achieve. There you ...
(Date:2/1/2016)... 1, 2016 Rising sales of ... global touchfree intuitive gesture control market size ... sales of consumer electronics coupled with new technological advancements ... size through 2020   --> ... new technological advancements to drive global touchfree intuitive gesture ...
Breaking Biology News(10 mins):